Every 8-K that NATURE'S MIRACLE HLDG INC (NMHI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NMHI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NMHI filings page.
Nature’s Miracle Holding Inc. entered into a Settlement Agreement with 1800 Diagonal Lending LLC to resolve litigation over defaults under several convertible promissory notes. Claims with an asserted aggregate indebtedness of approximately $791,323.32, plus interest, were settled for a reduced $575,000 settlement amount.
The Settlement Amount will be satisfied through cash payments and conversion rights under certain notes. The Company agreed to reserve 222,000,000 shares of common stock for 1800 Diagonal and to increase its authorized share capital, reserving additional shares as needed by July 31, 2026. If the Company defaults on payments or share-reserve obligations, 1800 Diagonal may seek judgment for the full asserted amount and permanent injunctive relief, while full payment or conversion will lead to note cancellation and dismissal of the action.
Nature’s Miracle Holding Inc. announced that investors should no longer rely on its previously issued unaudited condensed consolidated financial statements as of and for the period ended September 30, 2025. Those statements, filed on Form 10-Q on November 14, 2025, omitted an amount in short term loans.
The company has restated its condensed financial statements for the three and nine months ended September 30, 2025 to properly record the short term loan and will file an amended Form 10-Q/A for that quarter. Management and the Audit Committee discussed these matters with the company’s independent registered public accounting firm and with WWC, P.C., its auditor for the fiscal year ended December 31, 2025.
Nature’s Miracle Holding Inc. reports a leadership change. Zhiyi (Jonathan) Zhang resigned as President of the company effective February 28, 2026, and stepped down from the board of directors and its committees effective December 31, 2025. The company states his resignation was not due to any disagreement over operations, policies, or practices. The board has appointed Jinlong (Frank) Du to Zhang’s former roles, consistent with a prior disclosure made on February 9, 2026.
Nature’s Miracle Holding Inc. entered into a settlement and mutual release agreement with Megaphoton, Inc. to resolve a contract-related lawsuit in the U.S. District Court for the Central District of California. Both sides agreed to dismiss all claims with prejudice and provided mutual releases without any admission of wrongdoing.
The company will issue unregistered common shares as settlement consideration in a private placement relying on Section 4(a)(2) of the Securities Act; these “Settlement Shares” will carry restrictive legends and be subject to Rule 144 resale limits until registered. Nature’s Miracle also signed an employment agreement with a new executive who will serve as President and a director. The executive’s base salary must be at least equal to the chief executive officer’s total annual salary and remuneration, with a minimum of $300,000 per year through January 31, 2029, and automatic one-year renewals unless either party gives timely notice.
Nature’s Miracle Holding Inc. (NMHI) has amended its charter to sharply increase its authorized common stock. The company filed a Certificate of Amendment in Delaware to raise its authorized common stock, par value $0.0001 per share, from 100,000,000 shares to 1,000,000,000 shares.
This change was approved by written consent of shareholders holding a majority of the voting power of the outstanding common and preferred stock, following a recommendation by the Board of Directors. The higher authorization does not by itself issue new shares, but it allows the company to issue additional equity in the future for purposes such as financings, acquisitions or equity incentives if it chooses to do so.
Nature’s Miracle Holding Inc. (NMHI) entered financing and governance agreements. The company agreed to sell up to 2,000 shares of Series D Preferred Stock at $1,000 per share. An initial 500 shares closed for $500,000; a second 500-share closing for $500,000 is due before October 30, 2025, and a final 1,000-share closing for $1,000,000 is planned prior to an uplisting application. The Series D carries an 8% dividend and is convertible at $0.1180 per share, subject to a 4.99% beneficial ownership cap.
Separately, NMHI and GHS Investments LLC entered an agreement for 50 shares of Series A Preferred Stock in consideration of the investor’s consent to previously disclosed actions, including issuing 5,000 shares of Series B (with 20‑to‑1 super voting rights), 9,500 shares of Series C for an asset acquisition from CEO James Li, and a $3,000,000 promissory note to an affiliate of James Li. The Series A has a 12% dividend, a $1,200 stated value, and converts at $0.112 per share with a 4.99% cap. NMHI filed a Series D Certificate of Designations and related amendments, and increased designated Series B Preferred shares to 300. The securities were sold as unregistered under Section 4(a)(2) and/or Regulation D.
Nature's Miracle Holding Inc. filed an 8-K disclosing corporate actions dated September 18, 2025. The filing lists executed documents including a Membership Interest Purchase Agreement and a Promissory Note each dated September 18, 2025, plus a Certificate of Designation for Series B, an Amendment No. 1 to that certificate, and a Certificate of Designation for Series C. The filing identifies the company headquarters in Ontario, CA 91761 and is signed by Tie (James) Li, Chief Executive Officer. The document attaches an Inline XBRL cover page file. No financial amounts, purchaser/seller identities beyond the exhibit titles, or detailed transaction terms are provided in the disclosed text.